

Baptist Health South Florida

## Scholarly Commons @ Baptist Health South Florida

---

All Publications

---

12-5-2018

### Impact of a urinary tract infection treatment pathway on antimicrobial prescribing within a community hospital

Alyssa Donadio

*Miami Cancer Institute*, [alyssad@baptisthealth.net](mailto:alyssad@baptisthealth.net)

Heidi Clarke

*Baptist Hospital of Miami*, [heidic@baptisthealth.net](mailto:heidic@baptisthealth.net)

Erika Dittmar

*Baptist Hospital of Miami*, [erikaco@baptisthealth.net](mailto:erikaco@baptisthealth.net)

Follow this and additional works at: <https://scholarlycommons.baptisthealth.net/se-all-publications>



Part of the [Bacterial Infections and Mycoses Commons](#), [Chemical Actions and Uses Commons](#), and the [Pharmacy and Pharmaceutical Sciences Commons](#)

---

#### Citation

Donadio, Alyssa; Clarke, Heidi; and Dittmar, Erika, "Impact of a urinary tract infection treatment pathway on antimicrobial prescribing within a community hospital" (2018). *All Publications*. 3102.

<https://scholarlycommons.baptisthealth.net/se-all-publications/3102>

This Conference Poster -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly Commons @ Baptist Health South Florida. For more information, please contact [Carrief@baptisthealth.net](mailto:Carrief@baptisthealth.net).

## Background

Treatment algorithms and clinical practice guidelines are often implemented within healthcare institutions as measures to reduce healthcare costs while improving patient outcomes. As antibiotic resistance rates continue to rise and therapeutic options remain limited, urinary tract infections (UTIs) represent a growing public health concern.

Based on the institutional formulary, clinical experience, local resistance patterns, and consensus guidelines, the P&T Committee at Baptist Health South Florida agreed upon an evidence-based treatment pathway for UTIs to be used as guidance for empiric antibiotic treatment. The goal of this study was to assess whether this pathway is an effective antibiotic stewardship effort to promote appropriate antibiotic use.

## Purpose

To evaluate appropriateness of antibiotic selection and duration of treatment for urinary tract infections (UTIs) before and after implementation of a treatment pathway within Baptist Hospital of Miami.

## Methods

- ❖ Bi-phasic, IRB approved study conducted on adult patients admitted to Baptist Hospital of Miami
- ❖ Phase I was a retrospective chart review of 50 randomly selected patients admitted with a UTI between November 2016 and October 2017
- ❖ Phase II was a prospective review of 50 patients with a positive urine culture between January 2018 and March 2018, after implementation of the UTI treatment pathway
- ❖ Exclusion criteria:
  - Febrile neutropenia
  - Acute bacterial prostatitis
  - Coexisting infections
- ❖ Primary outcome: Percent of patients who received optimal empiric antibiotic treatment and duration of therapy before and after implementation of the pathway
- ❖ Secondary outcome: length of stay before and after pathway
- ❖ Appropriateness of antibiotic therapy was defined by the P&T approved treatment algorithm

## Demographics

	Phase I (n=50)	Phase II (n=50)	p value
<b>Patient characteristics</b>			
Average age, years	76	73	0.14
Gender—female, n (%)	37 (74%)	32 (64%)	0.28
Average baseline WBC count x10 <sup>9</sup> /L	10.3	11.2	0.30
<b>UTI category</b>			
Asymptomatic bacteriuria, n (%)	2 (4)	2 (4)	1.00
Acute uncomplicated cystitis, n (%)	12 (24)	13 (26)	0.82
Uncomplicated pyelonephritis, n (%)	14 (28)	12 (24)	0.65
Severe and/or complicated UTI, n (%)	22 (44)	23 (46)	0.84
ID Consult, n (%)	20 (40)	24 (48)	0.42

## Outcomes

	Phase I (n=50)	Phase II (n=50)	p value
<b>Primary Outcome</b>			
Optimal antibiotic & duration, n (%)	15 (30)	29 (58)	0.005
Optimal empiric antibiotic, n (%)	27 (54)	38 (76)	0.02
Optimal antibiotic duration, n (%)	27 (54)	37 (74)	0.038
<b>Secondary Outcome</b>			
Average length of stay, days	7.8	6.4	0.66
<b>Overall Outcomes</b>			
Average duration of therapy, days	8	6.7	0.03
Total days of antibiotic therapy	392	331	-
Opportunity for earlier IV to PO conversion, n (%)	19 (38)	9 (18)	0.03

Appropriateness of Antibiotic by UTI Category	Phase I (n=50)	Phase II (n=50)	p value
Asymptomatic bacteriuria, n (%)	0/2 (0%)	1/2 (50%)	0.32
Uncomplicated cystitis, n (%)	9/12 (75%)	13/13 (100%)	0.06
Uncomplicated pyelonephritis, n (%)	12/14 (86%)	12/12 (100%)	0.19
Severe and/or complicated UTI, n (%)	6/22 (27%)	12/23 (52%)	0.09

## Results

- There were no significant differences in baseline characteristic between the two groups
- The majority of patients were female and had a diagnosis of severe and/or complicated UTI
- For the primary outcome of optimal antibiotic selection and duration of therapy, 15 (30%) of the patients in phase I prior to pathway implementation were treated appropriately according to the algorithm, while 29 (58%) of patients were treated appropriately in phase II after pathway implementation (p=0.05)
- For the secondary outcome, average length of stay was reduced from 7.8 days in phase I to 6.7 days in phase II, although this difference was not found to be statistically significant (p=0.66)
- Average duration of therapy was reduced from 8 days during phase I to 6.7 days in phase II, which was statistically significant (p=0.03)

## Conclusion

Implementation of a UTI treatment pathway improved appropriate empiric antimicrobial use, reduced average length of stay, and reduced average duration of antimicrobial therapy, thus favoring patient outcomes and healthcare costs.

## References

1. Lopez ID, LeClaire AC, Martin CA, et al. Influence of a UTI empiric treatment pathway on physician prescribing in an academic medical center. *Formulary Journal Clinical Pharmacology*. 2006;41:74-81.
2. Flores-Mireles AL, Walker JN, Caparon M. & Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol*. 2015; 13(5): 269-284.

## Disclosure

All authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have direct or indirect interest in the subject matter of this presentation.